Twist Bioscience stock hits 52-week high at 143.1 USD
Twist Bioscience stock achieved a 52-week high of $143.10, trading at $143.35, just 0.96% below its peak. The company reported a 438% return over the past year and 349% gain year-to-date, leading to a market capitalization of $8.94 billion. Investors show strong confidence in Twist Bioscience's business prospects and biotechnology sector innovations.
The stock's price is volatile, with a beta of 2.16. Twist Bioscience reported revenue of $118.4 million in Q3 2026, surpassing expectations. However, adjusted earnings per share showed a loss of $0.56, wider than expected. The company has been involved in a stock purchase agreement with Invenra Inc. and serves as an independent evaluator in Anthropic's AI protein design project.
Despite skepticism from short seller Scorpion Capital, Twist Bioscience remains focused on its growth strategy and partnerships.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
